1.Livermore, DM, Canton, R, Gniadkowski, M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59:165–174.
2.Hawkey, PM, Jones, AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64(suppl 1):i3–i10.
3.Schwaber, MJ, Navon-Venezia, S, Kaye, KS, Ben-Ami, R, Schwartz, D, Carmeli, Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006;50:1257–1262.
4.Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 2007;60:913–920.
5.Melzer, M, Petersen, I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55:254–259.
6.Hyle, EP, Lipworth, AD, Zaoutis, TE, Nachamkin, I, Bilker, WB, Lautenbach, E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lacta-mase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005;165:1375–1380.
7.Graves, N, Harbarth, S, Beyersmann, J, Barnett, A, Halton, K, Cooper, B. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis 2010;50:1017–1021.
8.Graves, N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561–566.
9.Brun-Buisson, C, Roudot-Thoraval, F, Girou, E, Grenier-Sennelier, C, Durand-Zaleski, I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 2003;29:1464–1471.
10.Maragakis, LL, Perencevich, EN, Cosgrove, SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:751–763.
11.Beyersmann, J, Wolkewitz, M, Allignol, A, Grambauer, N, Schumacher, M. Application of multistate models in hospital epidemiology: advances and challenges. Biom J 2011;53:332–350.
12.Beyersmann, J, Kneib, T, Schumacher, M, Gastmeier, P. Nosocomial infection, length of stay, and time-dependent bias. Infect Control Hosp Epidemiol 2009;30:273–276.
13.Mauldin, PD, Salgado, CD, Hansen, IS, Durup, DT, Bosso, JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010;54:109–115.
14.Barnett, AG, Beyersmann, J, Allignol, A, Rosenthal, VD, Graves, N, Wolkewitz, M. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health 2011;14:381–386.
15.De Angelis, G, Allignol, A, Murthy, A, et al. Multistate modelling to estimate the excess length of stay associated with meticillin-resistant Staphylococcus aureus colonisation and infection in surgical patients. J Hosp Infect 2011;78:86–91.
16.Lambert, ML, Suetens, C, Savey, A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011;11:30–38.
17.Eggimann, P, Harbarth, S, Constantin, MN, Touveneau, S, Chevrolet, JC, Pittet, D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 2000;355:1864–1868.
18.Harbarth, S, Rohner, P, Auckenthaler, R, Safran, E, Sudre, P, Pittet, D. Impact and pattern of gram-negative bacteraemia during 6 y at a large university hospital. Scand J Infect Dis 1999;31:163–168.
19.Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.
20.Friedman, ND, Kaye, KS, Stout, JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791–797.
21.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard M7-A7. Wayne, PA: CLSI, 2006.
22.Aalen, O, Johansen, S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 1978;5:141–150.
23.Andersen, PK, Borgan, O, Gill, RD, Keiding, N. Statistical models based on counting processes. New York: Springer, 1993.
25.Hugonnet, S, Eggimann, P, Borst, F, Maricot, P, Chevrolet, JC, Pittet, D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004;25:1090–1096.
26.World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva: WHO, 2007.
28. Club d'utilisateurs APDRG Suisse. APDRG Suisse website. http://www.apdrgsuisse.ch. Published 2004. Accessed July 14, 2012.
29.Kronenberg, A, Hilty, M, Mühlemann, K. Temporal trends of Enterobacteriaceae with resistance to higher generation cepha-losporines in Switzerland, 2004 to 2010. In: Program and Abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases. May 7-10, 2011; Milan, Italy. Abstract P657.
32.Cosgrove, SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(suppl 2):S82–S89.
33.da Silva, GJ, Mendonça, N. Association between antimicrobial resistance and virulence in Escherichia coli. Virulence 2012;3:18–28.
34.Harbarth, S, Ferriere, K, Hugonnet, S, Ricou, B, Suter, P, Pittet, D. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002;137:1353–1359.
35.Tumbarello, M, Spanu, T, Di Bidino, R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010;54:4085–4091.
36.de Kraker, ME, Wolkewitz, M, Davey, PG, et al. Burden of an timicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66:398–407.
37.de Kraker, ME, Davey, PG, Grundmann, H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011;8:e1001104.
38.Lautenbach, E, Patel, JB, Bilker, WB, Edelstein, PH, Fishman, NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae, risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162–1171.
39.Blot, S, Vandewoude, K, De Bacquer, D, Colardyn, F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002;34:1600–1606.
40.Yang, YS, Ku, CH, Lin, JC, et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect 2010;43:194–199.